JPWO2020247790A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020247790A5
JPWO2020247790A5 JP2021571571A JP2021571571A JPWO2020247790A5 JP WO2020247790 A5 JPWO2020247790 A5 JP WO2020247790A5 JP 2021571571 A JP2021571571 A JP 2021571571A JP 2021571571 A JP2021571571 A JP 2021571571A JP WO2020247790 A5 JPWO2020247790 A5 JP WO2020247790A5
Authority
JP
Japan
Prior art keywords
therapeutic protein
target
unbound
abundance
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021571571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535042A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036380 external-priority patent/WO2020247790A1/en
Publication of JP2022535042A publication Critical patent/JP2022535042A/ja
Publication of JPWO2020247790A5 publication Critical patent/JPWO2020247790A5/ja
Pending legal-status Critical Current

Links

JP2021571571A 2019-06-05 2020-06-05 治療用タンパク質の属性を特定する方法 Pending JP2022535042A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962857637P 2019-06-05 2019-06-05
US62/857,637 2019-06-05
US202062968682P 2020-01-31 2020-01-31
US62/968,682 2020-01-31
PCT/US2020/036380 WO2020247790A1 (en) 2019-06-05 2020-06-05 Methods of identifying attributes of therapeutic proteins

Publications (2)

Publication Number Publication Date
JP2022535042A JP2022535042A (ja) 2022-08-04
JPWO2020247790A5 true JPWO2020247790A5 (es) 2023-06-07

Family

ID=71944196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571571A Pending JP2022535042A (ja) 2019-06-05 2020-06-05 治療用タンパク質の属性を特定する方法

Country Status (8)

Country Link
US (1) US20220260584A1 (es)
EP (1) EP3980786B1 (es)
JP (1) JP2022535042A (es)
AU (1) AU2020288652A1 (es)
CA (1) CA3138941A1 (es)
MA (1) MA56121A (es)
MX (1) MX2021014733A (es)
WO (1) WO2020247790A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065593A4 (en) * 2019-11-26 2024-04-03 Merck Sharp & Dohme LLC ULTRA-POWERFUL HYDROPHOBIC ONLINE INTERACTION CHROMATOGRAPHY FOR MONITORING AT LEAST ONE PRODUCT CHARACTERISTIC
EP4295158A1 (en) * 2021-02-19 2023-12-27 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
CN117716237A (zh) * 2021-07-13 2024-03-15 瑞泽恩制药公司 用于确定生物制剂的产物相关变体的基于质谱法的策略
MX2024001747A (es) 2021-08-06 2024-02-27 Amgen Inc Aislamiento de proteina terapeutica.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531390T1 (de) 2001-08-23 2011-11-15 Genmab As Interleukin-15-(il-15-)spezifische menschliche antikörper
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
AU2008265128A1 (en) 2007-06-20 2008-12-24 Irm Llc Methods and compositions for treating allergic diseases
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類

Similar Documents

Publication Publication Date Title
AU2020201695B2 (en) Biomarkers and methods for predicting preeclampsia
Boehmer et al. The proteomic advantage: label-free quantification of proteins expressed in bovine milk during experimentally induced coliform mastitis
Hunter et al. The functional proteomics toolbox: methods and applications
Weinberger et al. Surface-enhanced laser desorption–ionization retentate chromatography™ mass spectrometry (SELDI–RC–MS): a new method for rapid development of process chromatography conditions
US20070059776A1 (en) Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
Theodorescu et al. Mass spectrometry based proteomics in urine biomarker discovery
Jin et al. New developments in Western blot technology
JP2021534408A (ja) Ｄｅ ｎｏｖｏタンパク質シークエンシングのための方法
US20210109107A1 (en) Methods for characterizing host-cell proteins
Chen et al. Exploration of the normal human bronchoalveolar lavage fluid proteome
JP2022517338A (ja) 抗体の断片化を特定及び定量する方法及びシステム
Stigter et al. Coupling surface-plasmon resonance and mass spectrometry to quantify and to identify ligands
JPWO2020247790A5 (es)
JP2009531679A5 (ja) 複合タンパク質混合物中の被分析タンパク質および／または被分析ペプチドを検出および／または濃縮するための方法
CN113646638A (zh) 抗体电荷异质性的原生微流体ce-ms分析
Rabilloud Paleoproteomics explained to youngsters: How did the wedding of two-dimensional electrophoresis and protein sequencing spark proteomics on: Let there be light
Léger et al. Solid-phase hexapeptide ligand libraries open up new perspectives in the discovery of biomarkers in human plasma
Fertin et al. Strategy for purification and mass spectrometry identification of SELDI peaks corresponding to low-abundance plasma and serum proteins
JP2021016389A (ja) モノクローナル抗体の酵母による製造方法およびスクリーニング方法
KR101675303B1 (ko) 마이크로 중공사막 효소 반응기-텐덤 질량분석법을 이용한 단세포군 항체 기반 온라인 인단백질 프로테오믹스 분석방법
Korbakis et al. Delineating monoclonal antibody specificity by mass spectrometry
Silyavka et al. Collapsed monomolecular thin films as surface nanomodification techniques for bioorganic MALDI analysis
Boccardi et al. An automated plasma protein fractionation design: high-throughput perspectives for proteomic analysis
Klatt Microfluidic automation of sample preparation for mass spectrometry based proteomics
US20230089727A1 (en) Plasma proteomics profiling by automated iterative tandem mass spectrometry